TY - JOUR
T1 - Plasma basic fibroblast growth factor is correlated with plasminogen activator inhibitor-1 concentration in adults from the Veterans Affairs Diabetes Trial
AU - Zimering, Mark B.
AU - Anderson, Robert J.
AU - Luo, Ping
AU - Moritz, Thomas E.
N1 - Funding Information:
Supported by a grant from the Veterans Biomedical Research Institute, East Orange, NJ (to MBZ), and by the Cooperative Studies Program of the Department of Veterans Affairs, Office of Research and Development, Washington, DC. The authors report no conflicts of interest that would affect the objectivity of the findings presented.
PY - 2008/11
Y1 - 2008/11
N2 - Basic fibroblast growth factor (bFGF) is a potent mitogen in endothelial and vascular smooth muscle cells that increases in serum from adults with coronary artery disease and in microalbuminuric type 2 diabetes mellitus. There has been no prior study of plasma bFGF as a possible cardiovascular risk marker in type 2 diabetes mellitus. In this study, we tested for a correlation between log plasma bFGF immunoreactivity (bFGF-IR) and baseline cardiovascular risk factors in a baseline subset of subjects with advanced type 2 diabetes mellitus from the Veterans Affairs Diabetes Trial ([mean] age, 60 years; hemoglobin A1c, 9.5%; diabetes' duration, 11 years). Plasma bFGF-IR was determined with a sensitive, specific, 2-site enzyme-linked immunoassay in 281 patients at the baseline visit. Results were compared with baseline risk factors or baseline medication use. Baseline plasma bFGF-IR ranged from 0 to 141 pg/mL. Log plasma bFGF correlated significantly with non-Hispanic white race (P = .002), waist-hip ratio (P = .002), and plasminogen activator inhibitor-1 concentration (P <.0001). Log plasma bFGF correlated inversely with African American race (P = .0003). In multiple regression analysis, plasminogen activator inhibitor-1 and race were significantly correlated with log plasma bFGF. These results suggest a significant correlation between log plasma bFGF-IR and plasminogen activator inhibitor-1, a marker of hemostatic risk.
AB - Basic fibroblast growth factor (bFGF) is a potent mitogen in endothelial and vascular smooth muscle cells that increases in serum from adults with coronary artery disease and in microalbuminuric type 2 diabetes mellitus. There has been no prior study of plasma bFGF as a possible cardiovascular risk marker in type 2 diabetes mellitus. In this study, we tested for a correlation between log plasma bFGF immunoreactivity (bFGF-IR) and baseline cardiovascular risk factors in a baseline subset of subjects with advanced type 2 diabetes mellitus from the Veterans Affairs Diabetes Trial ([mean] age, 60 years; hemoglobin A1c, 9.5%; diabetes' duration, 11 years). Plasma bFGF-IR was determined with a sensitive, specific, 2-site enzyme-linked immunoassay in 281 patients at the baseline visit. Results were compared with baseline risk factors or baseline medication use. Baseline plasma bFGF-IR ranged from 0 to 141 pg/mL. Log plasma bFGF correlated significantly with non-Hispanic white race (P = .002), waist-hip ratio (P = .002), and plasminogen activator inhibitor-1 concentration (P <.0001). Log plasma bFGF correlated inversely with African American race (P = .0003). In multiple regression analysis, plasminogen activator inhibitor-1 and race were significantly correlated with log plasma bFGF. These results suggest a significant correlation between log plasma bFGF-IR and plasminogen activator inhibitor-1, a marker of hemostatic risk.
UR - http://www.scopus.com/inward/record.url?scp=53649096106&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=53649096106&partnerID=8YFLogxK
U2 - 10.1016/j.metabol.2008.06.012
DO - 10.1016/j.metabol.2008.06.012
M3 - Article
C2 - 18940395
AN - SCOPUS:53649096106
VL - 57
SP - 1563
EP - 1569
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
SN - 0026-0495
IS - 11
ER -